ELOXX PHARMACEUTICALS, INC. (ELOX) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income -$4.45M; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income -$3.79M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income -$1.58M; Depreciation and amortization (m).
- 2025-03-31: Basis Reported; EBITDA (m); Operating income -$1.22M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | (m) | -$4.45M | (m) | (m) | (m) | (m) | -$4.79M* | (m) | $2.84M | (m) | (m) |
| 2026-03-31 | Reported | (m) | -$3.79M | (m) | (m) | (m) | (m) | -$5.45M | (m) | (m) | (m) | (m) |
| 2025-06-30 | Reported | (m) | -$1.58M | (m) | (m) | (m) | (m) | -$1.75M* | (m) | $898.00K | (m) | (m) |
| 2025-03-31 | Reported | (m) | -$1.22M | (m) | (m) | (m) | (m) | $1.20M | (m) | (m) | (m) | (m) |
| 2023-09-30 | Reported | (m) | -$3.64M | (m) | (m) | (m) | $0.00* | -$3.45M* | (m) | (m) | (m) | (m) |
| 2023-06-30 | Reported | (m) | -$4.14M | (m) | (m) | (m) | $0.00* | -$2.07M* | (m) | (m) | (m) | (m) |
| 2023-03-31 | Reported | (m) | -$5.48M | (m) | (m) | (m) | $0.00 | -$6.81M | (m) | (m) | (m) | (m) |
| 2022-09-30 | Reported | (m) | -$7.14M | (m) | (m) | (m) | $48.00K* | -$6.95M* | (m) | (m) | (m) | (m) |
| 2022-06-30 | Reported | (m) | -$10.30M | (m) | (m) | (m) | $7.00K* | -$9.75M* | (m) | (m) | (m) | (m) |
| 2022-03-31 | Reported | (m) | -$10.95M | (m) | (m) | (m) | $11.00K | -$9.49M | (m) | (m) | (m) | (m) |
| 2021-09-30 | Reported | (m) | -$10.24M | (m) | (m) | (m) | (m) | -$7.59M* | (m) | (m) | (m) | (m) |
| 2021-06-30 | Reported | (m) | -$35.73M | (m) | (m) | (m) | (m) | -$9.80M* | (m) | (m) | (m) | (m) |
| 2021-03-31 | Reported | (m) | -$8.41M | (m) | (m) | (m) | (m) | -$7.68M | (m) | $4.07M | (m) | (m) |
| 2020-09-30 | Reported | (m) | -$6.30M | (m) | (m) | (m) | (m) | -$5.26M* | (m) | $3.40M | (m) | (m) |
| 2020-06-30 | Reported | (m) | -$7.59M | (m) | (m) | (m) | (m) | -$6.32M* | (m) | $3.70M | (m) | (m) |
| 2020-03-31 | Reported | (m) | -$13.77M | (m) | (m) | (m) | (m) | -$11.92M | (m) | $4.77M | (m) | (m) |
| 2019-09-30 | Reported | (m) | -$12.78M | (m) | (m) | (m) | $24.00K* | -$11.32M* | (m) | $6.80M | (m) | (m) |
| 2019-06-30 | Reported | (m) | -$14.31M | (m) | (m) | (m) | $0.00* | -$9.62M* | (m) | $7.34M | (m) | (m) |
| 2019-03-31 | Reported | (m) | -$11.98M | (m) | (m) | (m) | $16.00K | -$9.19M | (m) | $6.02M | (m) | $0.00 |
| 2018-09-30 | Reported | (m) | -$11.36M | (m) | (m) | (m) | $32.00K* | -$8.10M* | (m) | $5.42M | (m) | $0.00* |
| 2018-06-30 | Reported | (m) | -$13.54M | (m) | (m) | (m) | $44.00K* | -$8.51M* | (m) | $4.15M | (m) | $0.00* |
| 2018-03-31 | Reported | (m) | -$8.55M | (m) | (m) | (m) | $57.00K | -$5.70M | (m) | $4.39M | (m) | $0.00 |
| 2017-09-30 | Reported | (m) | -$4.00M | (m) | (m) | (m) | $59.00K* | -$575.32K | (m) | $3.28M | (m) | $0.00 |
| 2017-06-30 | Reported | (m) | -$3.18M | (m) | (m) | (m) | $22.00K* | -$3.17M* | (m) | $2.60M | (m) | (m) |
| 2017-03-31 | Reported | (m) | -$2.63M | (m) | (m) | (m) | $74.00K | -$2.73M | (m) | $2.35M | (m) | $0.00 |
| 2016-12-31 | Reported | (m) | -$1.51M | (m) | (m) | (m) | (m) | (m) | (m) | $207.38K | (m) | -$400.00K |
| 2016-09-30 | Reported | (m) | -$2.21M | (m) | (m) | (m) | (m) | -$573.74K | (m) | $280.24K | (m) | -$640.00K |
| 2016-03-31 | Reported | (m) | -$4.89M | (m) | (m) | (m) | $0.00* | (m) | (m) | $576.44K | (m) | -$400.00K |
| 2015-12-31 | Reported | (m) | -$3.76M | (m) | (m) | (m) | $0.00* | (m) | (m) | $594.50K | (m) | $0.00 |
| 2015-09-30 | Reported | (m) | -$1.15M | (m) | (m) | (m) | $0.00 | (m) | (m) | $601.58K | (m) | $0.00 |
| 2015-03-31 | Reported | (m) | -$1.22M | (m) | (m) | (m) | $6.21K* | (m) | (m) | $235.25K | (m) | $0.00 |
| 2014-12-31 | Reported | (m) | -$10.75M | (m) | (m) | (m) | $36.72K* | (m) | (m) | $1.37M | (m) | (m) |
| 2014-09-30 | Reported | (m) | -$5.19M | (m) | (m) | (m) | $74.33K | -$1.94M | (m) | $2.12M | (m) | (m) |
| 2014-03-31 | Reported | (m) | -$2.13M | (m) | (m) | (m) | $0.00* | -$1.56M* | (m) | $966.34K | (m) | (m) |
| 2013-12-31 | Reported | (m) | -$1.59M | (m) | (m) | (m) | $0.00* | -$1.42M* | (m) | $730.82K | (m) | (m) |
| 2013-09-30 | Reported | (m) | -$1.75M | (m) | (m) | (m) | $0.00 | -$670.47K | (m) | $810.94K | (m) | (m) |
| 2013-03-31 | Reported | (m) | -$1.04M | (m) | (m) | (m) | $0.00* | -$1.75M* | (m) | $492.85K | (m) | (m) |
| 2012-12-31 | Reported | (m) | -$1.30M | (m) | (m) | (m) | $0.00* | -$565.41K* | (m) | $591.08K | (m) | (m) |
| 2012-09-30 | Reported | (m) | -$1.25M | (m) | (m) | (m) | $1.28K | -$636.45K | (m) | $513.43K | (m) | (m) |
| 2012-03-31 | Reported | (m) | -$1.11M | (m) | (m) | (m) | $0.00* | -$980.02K* | (m) | $540.79K | (m) | (m) |
| 2011-12-31 | Reported | (m) | -$1.46M | (m) | (m) | (m) | (m) | -$1.21M* | (m) | $751.52K | (m) | (m) |
| 2011-09-30 | Reported | (m) | -$1.28M | (m) | (m) | (m) | (m) | -$1.09M | (m) | $634.19K | (m) | (m) |
| 2011-03-31 | Reported | (m) | -$1.37M | (m) | (m) | (m) | $0.00* | -$1.29M* | (m) | $800.34K | (m) | (m) |
| 2010-12-31 | Reported | (m) | -$1.51M | (m) | (m) | (m) | $0.00* | -$1.47M* | (m) | $798.35K | (m) | (m) |
| 2010-09-30 | Reported | (m) | -$2.21M | (m) | (m) | (m) | $2.03K | -$1.61M | (m) | $1.54M | (m) | (m) |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Reported | (m) | -$6.44M | (m) | (m) | (m) | (m) | -$6.33M | (m) | $3.06M | (m) | $0.00 |
| 2024-12-31 | Reported | (m) | -$2.47M | (m) | (m) | (m) | (m) | -$4.71M | (m) | $3.58M | (m) | $0.00 |
| 2023-12-31 | Reported | (m) | -$17.29M | (m) | (m) | (m) | (m) | -$14.34M | (m) | $8.60M | (m) | $0.00 |
| 2022-12-31 | Reported | (m) | -$34.42M | (m) | (m) | (m) | $66.00K | -$31.84M | (m) | (m) | (m) | $0.00 |
| 2021-12-31 | Reported | (m) | -$66.02M | (m) | (m) | (m) | $89.00K | -$35.00M | (m) | (m) | (m) | $0.00 |
| 2020-12-31 | Reported | (m) | -$33.45M | (m) | (m) | (m) | (m) | -$28.17M | (m) | $14.59M | (m) | $0.00 |
| 2019-12-31 | Reported | (m) | -$50.55M | (m) | (m) | (m) | $40.00K | -$39.39M | (m) | $26.35M | (m) | $0.00 |
| 2018-12-31 | Reported | (m) | -$47.56M | (m) | (m) | (m) | $235.00K | -$31.37M | (m) | $20.49M | (m) | $122.00K |
| 2017-12-31 | Reported | (m) | -$20.39M | (m) | (m) | (m) | $237.00K | -$15.94M | (m) | $16.40M | (m) | (m) |
| 2017-09-30 | Rolling | (m) | -$11.32M* | (m) | (m) | (m) | (m) | (m) | (m) | $8.44M* | (m) | (m) |
| 2017-06-30 | Reported | (m) | -$2.21M | (m) | (m) | (m) | $2.50K | (m) | (m) | $280.24K | (m) | -$640.00K |
| 2017-06-30 | Rolling | (m) | -$9.53M* | (m) | (m) | (m) | (m) | (m) | (m) | $5.44M* | (m) | (m) |
| 2016-12-31 | Reported | (m) | -$9.84M | (m) | (m) | (m) | $36.00K | -$8.84M | (m) | $8.99M | (m) | (m) |
| 2016-06-30 | Reported | (m) | -$11.19M | (m) | (m) | (m) | $0.00 | (m) | (m) | $2.18M | (m) | -$680.00K |
| 2015-12-31 | Reported | (m) | -$6.28M | (m) | (m) | (m) | $10.00K | -$5.74M | (m) | $5.84M | (m) | (m) |
| 2015-06-30 | Reported | (m) | -$18.08M | (m) | (m) | (m) | $122.64K | (m) | (m) | $4.57M | (m) | $0.00 |
| 2014-06-30 | Reported | (m) | -$9.15M | (m) | (m) | (m) | $3.19K | -$4.87M | (m) | $3.34M | (m) | $0.00 |
| 2013-06-30 | Reported | (m) | -$4.65M | (m) | (m) | (m) | $1.28K | -$3.90M | (m) | $2.09M | (m) | (m) |
| 2012-06-30 | Reported | (m) | -$5.41M | (m) | (m) | (m) | $4.46K | -$4.39M | (m) | $2.57M | (m) | (m) |
| 2011-06-30 | Reported | (m) | -$7.92M | (m) | (m) | (m) | $2.03K | -$5.39M | (m) | $3.72M | (m) | (m) |
| 2010-06-30 | Reported | (m) | -$4.85M | (m) | (m) | (m) | $1.12K | -$4.74M | (m) | $2.64M | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Tevogen Inc. (TVGN) | United States | $0.049B |